Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide + 2 L PEG versus split-dose 3 L PEG for bowel preparation before colonoscopy
ChiCTR2200057368Phase 4Not yet recruiting
- Sponsor
- Department of Gastroenterology, the First Affiliated Hospital of Shantou University
- Start
- Mar 2022
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of linaclotide and macrogol in Intestinal disease (2 arms), sponsored by Department of Gastroenterology, the First Affiliated Hospital of Shantou University. Primary endpoint: Boston bowel preparation score. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
linaclotidemacrogol
03
Conditions
Intestinal disease
Beyond the preview
Go deeper on ChiCTR2200057368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057368.